Dimethylstilbestrol
Dimethylstilbestrol[edit]

Dimethylstilbestrol (DMS) is a synthetic nonsteroidal estrogen of the stilbestrol group. It is chemically related to diethylstilbestrol (DES), which is more widely known and studied. DMS was developed in the early 20th century and has been used in various medical applications, although its use has declined due to safety concerns.
Chemical Properties[edit]
Dimethylstilbestrol is a stilbene derivative, characterized by its two phenyl rings connected by a carbon-carbon double bond. The chemical formula of DMS is C18H20O2. It is a crystalline solid at room temperature and is soluble in organic solvents.
Mechanism of Action[edit]
As an estrogen, DMS binds to and activates the estrogen receptors in the body. This activation leads to the transcription of estrogen-responsive genes, which can influence a variety of physiological processes, including the regulation of the menstrual cycle, maintenance of bone density, and modulation of lipid metabolism.
Medical Uses[edit]
Historically, dimethylstilbestrol was used in the treatment of menopausal symptoms, prostate cancer, and as a component of hormone replacement therapy. However, its use has been largely discontinued due to the discovery of significant adverse effects associated with similar compounds like diethylstilbestrol.
Adverse Effects[edit]
The use of synthetic estrogens like DMS has been associated with an increased risk of thromboembolic events, breast cancer, and endometrial cancer. These risks have led to a reevaluation of the safety of such compounds, and they are now rarely used in clinical practice.
Historical Context[edit]
Dimethylstilbestrol was developed during a period when synthetic estrogens were being explored for a variety of medical applications. The adverse effects observed with diethylstilbestrol, particularly its teratogenic effects when used during pregnancy, have overshadowed the use of DMS and similar compounds.
Related Compounds[edit]
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian